乳腺癌内分泌耐药的临床研究进展  

Clinical research of endocrine resistance in breast cancer

作　　者：李蔚冰[1] 徐绮腻[2] 

机构地区：[1]汕头市中心医院肿瘤内科,515041 [2]汕头大学医学院附属肿瘤医院内科

出　　处：《国际肿瘤学杂志》2013年第7期509-511,共3页Journal of International Oncology

摘　　要：内分泌治疗是激素受体阳性乳腺癌的重要系统治疗手段，但原发性与继发性耐药是当前内分泌治疗的难题。雌激素受体通路与其他受体通路的交互效应是耐药机制之一。抑制磷脂酰肌醇3-激酶（P13K）-蛋白激酶B（Akt）-哺乳动物雷帕霉素靶蛋白（mTOR）、表皮生长因子受体（EGFR）等分子通路逆转内分泌耐药的临床研究已取得一定的成果。Endocrine therapy is the most important systemic therapy for hormone receptor positive breast cancer. However, intrinsic or acquired resistance to endocrine therapy is a challenge currently. Crosstalk between estrogen receptor pathway and other pathway is considered to be one of the underlying mechanisms. Progress has been made in reversing resistance by blocking signaling through pathways such as the phosphoinositide 3-kinases- protein kinase B-mammalian target of rapamycin and epidermal growth factor receptor pathway.

关 键 词：乳腺肿瘤 受体 雌激素 内分泌治疗 

分 类 号：R737.9[医药卫生—肿瘤]